National Key Research and Development Program of China
Organisation
Trials
Collaborator, Phase 4, Status unknown, 96 people, 18 Apr 2023
Funded papers
SGLT2 inhibitor ameliorates hypertension by regulating the CYP4A/20-HETE pathway in the kidney
2022YFC3400700, 21 Oct 2026
2022YFC3501100; 2022YFC3501102, 12 Oct 2026
2023YFC2507203, 12 Oct 2026
No.2023YFC3504300, 11 Oct 2026
2023YFA1800800, 10 Oct 2026
Silicate Biomaterials-Stimulated Vascularized Callus Organoids for Bone Tissue Regeneration
2024YFC2418700, 10 Oct 2026
2021YFA1100600, 8 Oct 2026
2024YFC2418800, 7 Oct 2026
2022YFC2505100, 2022YFC2505103, 7 Oct 2026
2025YFC3610200, 2023YFC3603800, 2023YFC3603804, 6 Oct 2026
Nos2020YFC2009000, 6 Oct 2026
2025YFE0151900, 2023YFE0112300, 6 Oct 2026
2023YFE0208700, 6 Oct 2026
Endowing Flexibility of Alveolar Type II Cells to Recapitulate Development From Lung Bud to Alveoli
2024YFA1107601, 4 Oct 2026
CHAIR an antigen-resolved antibody-reactome resource for healthy adult immune aging
2023YFC2307200, 2024YFA1307600, 2024YFA1307601, 2024YFA1307602, 2024YFA1307603, 2024YFA1307604, 4 Oct 2026
2022YFC3600203, 3 Oct 2026
2020YFC2002800, 2 Oct 2026
2016YFC0900500, 2 Oct 2026
Ferro-aging: iron-lipid axis in systemic decline
2 Oct 2026
2023YFB3210301, 1 Oct 2026
Sources: api.crossref.org
Papers
Human reproduction (Oxford, England), 28 Aug 2026
ADA Scientific Sessions 2025 abstract, 13 Jun 2025
ADA Scientific Sessions 2025 abstract, 13 Jun 2025
ADA Scientific Sessions 2025 abstract, 13 Jun 2025